Tesamorelin is one of a small number of growth-hormone-releasing peptides that is an actual FDA-approved prescription drug rather than a research chemical, but its approval is narrower than the way it's often marketed suggests.

What It Is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), built from the same 44-amino-acid sequence as the natural hormone with an added chemical group that slows its breakdown and extends how long it stays active in the body. It's administered as a daily subcutaneous injection. Like sermorelin and CJC-1295, discussed elsewhere on this site, tesamorelin works upstream of growth hormone itself, stimulating the pituitary gland to release more of its own growth hormone rather than supplying growth hormone directly.

What It's Actually FDA-Approved For

The FDA approved tesamorelin, marketed as Egrifta and later as the once-weekly formulation Egrifta WR, specifically for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy, a fat-redistribution condition associated with HIV infection and some antiretroviral treatments. That is the entire approved indication. It is not approved as a general anti-aging therapy, a bodybuilding aid, or a treatment for age-related weight gain in people without HIV-associated lipodystrophy, despite frequently being marketed that way in wellness and longevity contexts.

What the Clinical Evidence Shows

The Phase 3 trials that supported approval measured visceral fat reduction using CT imaging in HIV patients with lipodystrophy, and both trials exceeded the pre-specified 8% reduction threshold, with reductions in the range of 14% to 18%. Effects on blood lipids were less consistent, reaching statistical significance in only one of the two trials. Notably, the approval was based on a body-composition endpoint, not on a demonstrated improvement in cardiovascular outcomes or mortality; long-term cardiovascular benefit has not been established, and some insurers have characterized the treatment's benefit as cosmetic for coverage purposes.

Off-Label Marketing and What It Leaves Out

Because tesamorelin is a real, manufactured, approved drug rather than a compounded research chemical, its purity and dosing are standardized in a way that unregulated growth-hormone secretagogues typically are not. That legitimacy is part of why it gets marketed off-label to people without HIV-associated lipodystrophy who are interested in reducing visceral fat or supporting body composition generally. Using an approved drug for an indication it wasn't approved for is a real and common practice in medicine, off-label prescribing happens across many drug classes, but it means the specific evidence of benefit and safety that supported tesamorelin's approval does not automatically extend to a different patient population or a different goal.

The Bottom Line

Tesamorelin's story is a useful contrast to many of the research peptides covered on this site: it has gone through FDA review, has standardized manufacturing, and has real Phase 3 human trial data behind it, but that data supports a specific, narrow use in a specific patient population, not the broader anti-aging or fitness claims sometimes attached to it. Anyone considering tesamorelin, whether for its approved indication or off-label, should discuss their goals, medical history, and the actual strength of the supporting evidence with a licensed physician.